Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRIGrowth Rate was -43.60% per year.
During the past 13 years, PT Kimia Farma Persero Tbk's highest 3-Year average EPS without NRI Growth Rate was 51.30% per year. The lowest was -139.60% per year. And the median was 10.00% per year.
PT Kimia Farma Persero Tbk (ISX:KAEF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
PT Kimia Farma Persero Tbk Earnings per Share (Diluted) Related Terms
PT Kimia Farma Persero Tbk Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for PT Kimia Farma Persero Tbk's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk Earnings per Share (Diluted) Chart
ISX:KAEF vs MCK, COR, CAH: Earnings per Share (Diluted) Comparison
For the Medical Distribution subindustry, PT Kimia Farma Persero Tbk's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Persero Tbk PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Persero Tbk's PE Ratio distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Persero Tbk's PE Ratio falls into.
PT Kimia Farma Persero Tbk Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
PT Kimia Farma Persero Tbk's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-41.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of Rp-41.25 mean?
PT Kimia Farma Persero Tbk (ISX:KAEF) has a Earnings per Share (Diluted) of Rp-41.25 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on PT Kimia Farma Persero Tbk and its competitors. According to the industry distribution chart, PT Kimia Farma Persero Tbk ranks #92 out of 102 companies in the Medical Distribution industry, placing it in the top 90.2%.
Is PT Kimia Farma Persero Tbk's Earnings per Share (Diluted) too high?
PT Kimia Farma Persero Tbk's current Earnings per Share (Diluted) is Rp-41.25. Based on the distribution chart, PT Kimia Farma Persero Tbk ranks #92 out of 102 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's Earnings per Share (Diluted) compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Persero Tbk ranks #92 out of 102 companies for Earnings per Share (Diluted). This places PT Kimia Farma Persero Tbk in the lower half of its industry. The industry median Earnings per Share (Diluted) is 3.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Distribution company?
The median Earnings per Share (Diluted) among Medical Distribution companies is 3.10, based on 102 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on PT Kimia Farma Persero Tbk and its competitors. For the Medical Distribution industry, the median Earnings per Share (Diluted) is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Persero Tbk's current Earnings per Share (Diluted) is Rp-41.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp574.38, compared to a current price of Rp440.00 — trading 23.4% below its estimated fair value. The current Earnings per Share (Diluted) is Rp-41.25. PT Kimia Farma Persero Tbk's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current Earnings per Share (Diluted) is Rp-41.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp440.00 is trading 23.4% below its estimated GF Value™ of Rp574.38.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
Earnings per Share (Diluted): Rp-41.25
GF Value™: Rp574.38 vs. price of Rp440.00 (23.4% below fair value)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
53GF Score
Get the complete analysis for ISX:KAEF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
